Search Results
Search for other papers by David Taïeb in
Google Scholar
PubMed
Search for other papers by Christelle Fargette in
Google Scholar
PubMed
Search for other papers by Abhishek Jha in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Nuclear medicine as a component of precision medicine This article is a summary of a plenary lecture presented at the 6th International Symposium on Pheochromocytoma/Paraganglioma (20 October 2022, Prague, Czech Republic), which explored the
Search for other papers by Masaki Shiota in
Google Scholar
PubMed
Search for other papers by Shusuke Akamatsu in
Google Scholar
PubMed
Search for other papers by Shigehiro Tsukahara in
Google Scholar
PubMed
Search for other papers by Shohei Nagakawa in
Google Scholar
PubMed
Search for other papers by Takashi Matsumoto in
Google Scholar
PubMed
Search for other papers by Masatoshi Eto in
Google Scholar
PubMed
mutations has been suggested, and information about the mutation status could contribute to the selection of effective treatment for individual patients. Currently, precision medicine utilizing genetic and genomic data is becoming to play an increasingly
Search for other papers by Bethany Smith in
Google Scholar
PubMed
Search for other papers by Priyanka Agarwal in
Google Scholar
PubMed
Greater Los Angeles Veterans Administration, Los Angeles, California, USA
Search for other papers by Neil A Bhowmick in
Google Scholar
PubMed
Introduction Precision medicine refers to leveraging larger scale somatic or genomic data in the informing medical decision-making. Although the principles of precision medicine are extending into proteomics and metabolomics, a vast amount of
Search for other papers by Lamis Yehia in
Google Scholar
PubMed
Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Germline High Risk Cancer Focus Group, CASE Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA
Search for other papers by Charis Eng in
Google Scholar
PubMed
serving as a model for precision medicine ( Eng 2000 , Tan et al . 2012 , Mester & Eng 2013 , Tilot et al . 2015 , Ngeow et al . 2017 ). Cowden syndrome (CS; MIM 158350) is an autosomal dominant multi-system disorder characterized by multiple
Search for other papers by Fabio R Faucz in
Google Scholar
PubMed
Search for other papers by Anelia D Horvath in
Google Scholar
PubMed
Endocrine Department, Center for Rare Adrenal Diseases, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Guillaume Assié in
Google Scholar
PubMed
Adrenal Unit, Laboratory of Molecular and Cellular Endocrinology LIM/25, Division of Endocrinology and Metabolism, University of Sao Paulo Medical School, São Paulo, Brasil
Search for other papers by Madson Q Almeida in
Google Scholar
PubMed
Search for other papers by Eva Szarek in
Google Scholar
PubMed
Search for other papers by Sosipatros Boikos in
Google Scholar
PubMed
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Search for other papers by Isaac Levy in
Google Scholar
PubMed
Search for other papers by Andrea G Maria in
Google Scholar
PubMed
Search for other papers by Ajay Chitnis in
Google Scholar
PubMed
Search for other papers by Cristina R Antonescu in
Google Scholar
PubMed
Search for other papers by Rainer Claus in
Google Scholar
PubMed
Endocrine Department, Center for Rare Adrenal Diseases, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
Search for other papers by Christoph Plass in
Google Scholar
PubMed
Search for other papers by Charis Eng in
Google Scholar
PubMed
Human Genetics & Precision Medicine, IMBB, Foundation for Research & Technology Hellas, Heraklion, Crete, Greece
Research Institute, ELPEN, Pikermi, Athens, Greece
Search for other papers by Constantine A Stratakis in
Google Scholar
PubMed
, Inc. and Sync, Inc.; he is also the director of Genetics & Precision Medicine, at FORTH ( www.forth.gr ); none of these activities conflict with the contents of this article. F.R.F. holds a patent on the GPR101 gene and/or its function. The other
Search for other papers by Xumeng Wang in
Google Scholar
PubMed
Search for other papers by Tianxing Ying in
Google Scholar
PubMed
Search for other papers by Jimeng Yuan in
Google Scholar
PubMed
Search for other papers by Yue Wang in
Google Scholar
PubMed
Search for other papers by Xingyun Su in
Google Scholar
PubMed
Search for other papers by Shitu Chen in
Google Scholar
PubMed
Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China
Search for other papers by Yurong Zhao in
Google Scholar
PubMed
Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China
Search for other papers by Yuanyuan Zhao in
Google Scholar
PubMed
Institute of Environmental Medicine of Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China
Search for other papers by Jinghao Sheng in
Google Scholar
PubMed
Search for other papers by Lisong Teng in
Google Scholar
PubMed
Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China
Search for other papers by Chi Luo in
Google Scholar
PubMed
Search for other papers by Weibin Wang in
Google Scholar
PubMed
& Pietzsch J 2007 L-type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18F-fluoro-L-dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo . Journal of Nuclear Medicine 48 2063 – 2071 . ( https://doi.org/10
Search for other papers by David Taïeb in
Google Scholar
PubMed
Search for other papers by Abhishek Jha in
Google Scholar
PubMed
Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland
Health Technology Assessment Unit, General Directorate, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
Search for other papers by Giorgio Treglia in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
nor ethical. Therefore, adoption of a composite of imaging and/or pathologic findings should be considered a robust alternative ( Hofman & Hicks 2015 ). Theranostics Personalized (precision) medicine has already made its mark and has the
Search for other papers by Nely Díaz-Mejía in
Google Scholar
PubMed
Search for other papers by David García-Illescas in
Google Scholar
PubMed
Search for other papers by Rafael Morales-Barrera in
Google Scholar
PubMed
Search for other papers by Cristina Suarez in
Google Scholar
PubMed
Search for other papers by Jacques Planas in
Google Scholar
PubMed
Search for other papers by Xavier Maldonado in
Google Scholar
PubMed
Search for other papers by Joan Carles in
Google Scholar
PubMed
Search for other papers by Joaquin Mateo in
Google Scholar
PubMed
genomic landscape of lethal prostate cancer allows for reclassifying this disease based on predictive biomarkers for specific drugs, aiming for accelerating the development of precision medicine strategies for advanced prostate cancer. The recent approvals
Search for other papers by Sergio Vargas-Salas in
Google Scholar
PubMed
Search for other papers by José R Martínez in
Google Scholar
PubMed
Search for other papers by Soledad Urra in
Google Scholar
PubMed
Search for other papers by José Miguel Domínguez in
Google Scholar
PubMed
Search for other papers by Natalia Mena in
Google Scholar
PubMed
Search for other papers by Thomas Uslar in
Google Scholar
PubMed
Search for other papers by Marcela Lagos in
Google Scholar
PubMed
Search for other papers by Marcela Henríquez in
Google Scholar
PubMed
Search for other papers by Hernán E González in
Google Scholar
PubMed
emergence of precision medicine has changed the paradigm of ITC management. The first test released to the market was the Afirma gene expression classifier (Afirma-GEC) ( Alexander et al. 2012 ), followed by ThyGenX/ThyraMIR ( Labourier et al. 2015
Department of Pathology and Molecular Medicine, Queen’s University, Kingston, Ontario, Canada
Search for other papers by Lois M Mulligan in
Google Scholar
PubMed
the molecular effects of disease mutations, the mechanisms by which they cause cellular dysfunctions and the implications of these at the organismal level underlie the great strength of precision medicine to effectively target the patient’s needs and